Asia shares wobble; bitcoin rallies on 'Trump trade'
Harris campaign reports spending $270 million in Sept, well above Trump's outlays of $78 million
Indonesia's Prabowo plans military academy retreat for new cabinet
Indonesia's Prabowo to swear in cabinet of over 100 ministers, deputies
Thailand says investment pledges at 10-year high in Jan-Sept
Australia's Qantas told to pay $114,000 to 3 sacked workers in landmark outsourcing case
New York wins first WNBA championship after falling in previous five appearances in the Finals
Dodgers finish off Mets with 10-5 win in NLCS and advance to face Yankees in World Series
Donald Trump stops by primetime NFL matchup between the Jets and Steelers to cap dizzying weekend
By Svea Herbst-Bayliss
(Reuters) -Hedge fund Starboard Value has taken a stake in Kenvue, the consumer products company that makes Band-Aid, Listerine, and Tylenol, and which went public last year, two people familiar with the matter said on Sunday.
Reuters was not able to immediately learn the size of the stake.
Kenvue, previously a part of Johnson & Johnson, has seen its stock price fall 18% since the company was listed publicly in May, 2023. It closed trading at $21.72 per share on Friday, giving the company a market value of $41 billion.
Starboard may want the company to review how it positions its brands and how they are priced in order to boost its performance, one of the sources said.
The sources were not authorised to discuss the hedge fund's positions publicly and declined to be identified. A Kenvue representative was not immediately available for comment.
The news, first reported by the Wall Street Journal, comes two days before the 13D Monitor Active-Passive Investor Summit where Starboard chief investment officer, Jeffrey Smith, is scheduled to present investment ideas.
At the conference, Starboard is expected to discuss its new roughly $1 billion investment in pharmaceutical company Pfizer. The hedge fund has signaled that it wants the pharmaceutical giant to improve its financial performance.
Smith met last week with Pfizer CEO Albert Bourla and the company's lead independent director. Pfizer delivered the world's first COVID-19 vaccine but its stock price has lost nearly half of its value since 2021 when demand for the vaccine was high.
(Reporting by Svea Herbst-Bayliss in New York and Chandni Shah in Bengaluru; Editing by Subhranshu Sahu and Edwina Gibbs)
